Eye surgery

Worldwide Corneal Implants Industry to 2026 - North America Accounted for the Largest Share in the Global Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
General Health, Optical, Health, Surgery, Medical specialties, Clinical medicine, Medicine, Eye surgery, Corneal transplantation, Corneal ulcer, Ophthalmology, Keratoconus, Peter Hersh

Penetrating keratoplasty procedures are performed to treat patients suffering from eye disorders such as corneal ulcers and infectious keratitis.

Key Points: 
  • Penetrating keratoplasty procedures are performed to treat patients suffering from eye disorders such as corneal ulcers and infectious keratitis.
  • Hence the increasing number of penetrating keratoplasty procedures performed indicates the rising demand for corneal implants.
  • Within North America, the United States has held the major share of the market and expected to dominate the forecast period.
  • Thus, in view of the above-mentioned factors, the market growth will boost in North America.

Holland Foundation For Sight Restoration Launched To Provide Life Changing Eye Surgeries

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Clinical medicine, Medicine, Eye surgery, Corneal transplantation, Sight restoration, Cornea, Organ transplantation, ASCRS, Ophthalmology, Fuchs' dystrophy, Boston keratoprosthesis

The announcement of The Holland Foundation was made during the American Society of Cataract & Refractive Surgery (ASCRS ) annual meeting in Las Vegas.

Key Points: 
  • The announcement of The Holland Foundation was made during the American Society of Cataract & Refractive Surgery (ASCRS ) annual meeting in Las Vegas.
  • "To treat these patients, we transplant the specialized surface cells of the eye from a relative or a deceased donor.
  • The Holland Foundation for the Restoration of Sight will:
    Provide support and clinical care for patients with severe ocular surface disease throughout the nation.
  • The goal of the Holland Foundation for Sight Restoration established as a 501(c)(3) is to address a significant unmet need of corneal transplantation for patients who have Severe Ocular Surface Disease.

Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Research, Surgery, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Optical, Science, Other Science, Ophthalmology, Medical specialties, Clinical medicine, Eye surgery, Cataract surgery, Lenses, Cataract

Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter financial results on Monday, August 9, 2021.

Key Points: 
  • Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter financial results on Monday, August 9, 2021.
  • Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Companys financial results and provide a general business update.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Friday, July 23, 2021
Research, Surgery, Clinical trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Eye surgery, Clinical medicine, Medical specialties, Medicine, Cataract surgery, ASCRS, Cataract, Refractive surgery

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held July 23-27, 2021 in Las Vegas, NV.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held July 23-27, 2021 in Las Vegas, NV.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
  • Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors.

Johnson & Johnson Vision Introduces VERITAS Vision System With Features To Address Key Unmet Needs In Cataract Surgery

Retrieved on: 
Friday, July 23, 2021
Ophthalmology, Medicine, Medical specialties, Eye surgery, Cataract surgery, Johnson & Johnson, Phacoemulsification, Cataract

** "The advancements Johnson & Johnson Vision has made in phaco technology reinforce that the company is listening and tailoring innovations to surgeons' needs.

Key Points: 
  • ** "The advancements Johnson & Johnson Vision has made in phaco technology reinforce that the company is listening and tailoring innovations to surgeons' needs.
  • "Our VERITAS Vision System delivers high-performing, reliable tools for a smooth, effective cataract surgery for patients while also prioritizing surgeon well-being."
  • At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide.
  • * Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Johnson & Johnson Vision Introduces VERITAS Vision System With Features To Address Key Unmet Needs In Cataract Surgery

Retrieved on: 
Friday, July 23, 2021
Ophthalmology, Medicine, Medical specialties, Eye surgery, Cataract surgery, Johnson & Johnson, Phacoemulsification, Cataract

SANTA ANA, Calif., July 23, 2021 /PRNewswire/ -- Johnson & Johnson Vision,* a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies,† today announced the global availability of the VERITAS Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort. The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting.

Key Points: 
  • ** "The advancements Johnson & Johnson Vision has made in phaco technology reinforce that the company is listening and tailoring innovations to surgeons' needs.
  • "Our VERITAS Vision System delivers high-performing, reliable tools for a smooth, effective cataract surgery for patients while also prioritizing surgeon well-being."
  • At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide.
  • * Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Thursday, July 22, 2021
Medical devices, Health, Surgery, Pharmaceutical, Optical, Biotechnology, Eye surgery, ASCRS, Cataract surgery, Photrexa® Viscous and Photrexa, Glaukos, PHOTREXA® VISCOUS AND PHOTREXA, GLAUKOS

The faculty includes Richard Lindstrom, MD (Moderator); Mark Gallardo, MD; Leon Herndon, MD; Deborah Ristvedt, DO; and Thomas Samuelson, MD.

Key Points: 
  • The faculty includes Richard Lindstrom, MD (Moderator); Mark Gallardo, MD; Leon Herndon, MD; Deborah Ristvedt, DO; and Thomas Samuelson, MD.
  • Experience with Second-Generation Trabecular Micro-Bypass Implantation with Cataract Surgery, Either with or without Ab-Interno Canaloplasty
    Corneal Cross-Linking Outcomes in Patients with Thin Corneas: Can We Help More Patients with Keratectasia?
  • Glaukos will also be exhibiting on the showroom floor throughout ASCRS at booth #3025.
  • The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

Retrieved on: 
Monday, July 19, 2021
Ophthalmology, Anatomy, Human eye, Cornea, Stroma of cornea, Eye surgery, Rare diseases

The biosynthetic cornea, that is optically clear, offers an alternative using human Type III collagen, a key structural protein that is found in normal human corneas and therefore does not require immunosuppressive medications.

Key Points: 
  • The biosynthetic cornea, that is optically clear, offers an alternative using human Type III collagen, a key structural protein that is found in normal human corneas and therefore does not require immunosuppressive medications.
  • Under the terms of the agreement, Eluminex will make an $8 million upfront payment to FibroGen.
  • In addition, FibroGen may receive up to a total of $64 million in future manufacturing, clinical, regulatory, and commercial milestone payments for the biosynthetic cornea program, as well as $36 million in commercial milestones for the first recombinant collagen III product that is not the biosynthetic cornea.
  • The Eluminex biosynthetic cornea (EB-301) is a clinical stage corneal stromal substitute that will be initially developed for the China market.

iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients

Retrieved on: 
Thursday, July 15, 2021
Medicine, Eye surgery, Clinical medicine, Medical specialties, Glaucoma, Cataract surgery, Implant, Minimally invasive glaucoma surgery, Draft:Martin Uram

This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.

Key Points: 
  • This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.
  • Patients will also be followed to evaluate long-term benefits and tolerability of MINIjectTM in the treatment of mild to moderate glaucoma.
  • Michel Vanbrabant, CEO of iSTAR Medical, commented "We are very pleased that the FDA has granted us approval to bring this innovative technology to North American patients suffering from primary open angle glaucoma in the STAR-V trial.
  • iSTAR Medical SA is a private med-tech company developing minimally invasive ophthalmic implants for the treatment of glaucoma patients.

iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients

Retrieved on: 
Thursday, July 15, 2021
Medicine, Eye surgery, Clinical medicine, Medical specialties, Glaucoma, Cataract surgery, Implant, Minimally invasive glaucoma surgery, Draft:Martin Uram

This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.

Key Points: 
  • This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.
  • Patients will also be followed to evaluate long-term benefits and tolerability of MINIjectTM in the treatment of mild to moderate glaucoma.
  • Michel Vanbrabant, CEO of iSTAR Medical, commented "We are very pleased that the FDA has granted us approval to bring this innovative technology to North American patients suffering from primary open angle glaucoma in the STAR-V trial.
  • iSTAR Medical SA is a private med-tech company developing minimally invasive ophthalmic implants for the treatment of glaucoma patients.